ImmunityBio Inc
IBRX
Market Cap$3.46B
Close$
$-1.26
114% downside
Current Fair Value
114% downsideOvervalued by 114% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.46 Billion |
|---|---|
| Enterprise Value | $3.82 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.15 |
| Beta | 0.0 |
| Outstanding Shares | 677,003,411 |
| Avg 30 Day Volume | 5,851,701 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.93 |
|---|---|
| PEG | -5.13 |
| Price to Sales | - |
| Price to Book Ratio | -8.99 |
| Enterprise Value to Revenue | 6133.7 |
| Enterprise Value to EBIT | -10.34 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...